Protocols by Charles Sieg

Supplements

Theracurmin HP

What the research says about this better-absorbed curcumin from turmeric, what it has and hasn't been shown to do, who paid for the studies, and the liver-injury reports tied to turmeric supplements.

Overall evidence Early20 sourcesReviewed November 5, 2026

Several small studies agree that this form gets far more curcumin into the blood, but the benefit trials of this product are small and mostly paid for by its developer, the stronger joint data come from other curcumin products, and turmeric supplements have been tied to liver injury.

The short version

  • I take Theracurmin HP from Integrative Therapeutics. It's curcumin from turmeric, dispersed as tiny colloidal particles so more of it reaches the blood1,2.
  • On absorption the evidence is consistent: in a crossover study of 24 healthy adults, exposure was 35.9 to 42.6 times higher than with plain curcumin powder3. Smaller studies agree, but they measure blood levels, not health1,4,5.
  • On benefits it gets thinner. A randomized trial of 50 people with knee osteoarthritis found less pain at 8 weeks, and an 18-month trial of 40 adults found memory gains6,7. Both are small, and Theravalues, the Japanese company that developed Theracurmin, financially supported the knee trial6.
  • The wider curcumin research on arthritis is more consistent, but it pools many different products8,9,10.
  • Turmeric supplements have caused liver injury, including one death among 10 cases in a US network, and in 7 Italian cases every product was a high-bioavailability formula at a high dose11,12.

The protocol

This is what the label and the research describe, not a prescription. My own dose and timing aren't listed here.

ParameterWhat the sources say
ProductTheracurmin HP: a serving is 2 capsules with 600 mg of Theracurmin, in 60- and 120-capsule bottles2,13
Label directionsAdults take 2 capsules daily or as recommended by a healthcare professional13
Curcumin contentA 2017 label gave the 600 mg as 30% curcumin, or 180 mg14. The current label record lists 600 mg of Theracurmin without that breakdown13
What the joint trials usedTheracurmin with 180 mg of curcumin a day, for 8 weeks to 12 months6,15
What the memory trial usedTheracurmin containing 90 mg of curcumin, twice daily, for 18 months7
What the absorption studies usedSingle doses from 30 mg to 210 mg of Theracurmin1,16
Wider curcumin meta-analysisAbout 1,000 mg of curcumin a day, from many different products8
TimingThe sources I opened don't specify a time of day or whether to take it with food

If the current capsules still carry 30% curcumin, as the 2017 label said, a 2-capsule serving matches the 180 mg of curcumin a day the joint trials used; the current label record doesn't say14,13,6. The wider curcumin research used far larger doses of other products, so its results don't transfer directly8.

How I use it

I take Theracurmin HP from Integrative Therapeutics. I haven't said here how much, when, or why.

Why it works

Plain curcumin is poorly absorbed, which is the whole reason this product exists. Theracurmin disperses curcumin as colloidal particles. In the original paper, exposure was more than 40-fold higher than with curcumin powder in rats and 27-fold higher in human volunteers given 30 mg1. In six healthy volunteers, plasma curcumin rose with the dose from 150 mg to 210 mg of Theracurmin, and the half-life was 9.7 to 13.0 hours16.

Against other branded curcumins, a double-blind crossover in 9 people found Theracurmin's peak 10.7 times higher than BCM-95 and 5.6 times higher than Meriva, though the products carried different amounts of curcumin4. A drinkable form beat three other curcumin beverages by 1.5 to 4.0 times on exposure5.

Better absorption is a means, not an outcome. Whether more curcumin in the blood means more benefit is what the trials below try to answer.

What the research says

Moderate It absorbs far better than curcumin powder. Small crossover and pharmacokinetic studies in healthy adults all point the same way1,16,5,4,3. The newest, a randomized three-period crossover in 24 adults, put the peak ratio at 18.4 to 20.5 and the exposure (AUC) ratio at 35.9 to 42.6 versus powder, with a median time to peak of 1.5 to 3 hours versus 8 hours3. Two caveats: these measure blood levels only, and most have company ties. The original paper's lead author is listed with Theravalues Corporation, the Morimoto and Sunagawa groups describe Theracurmin preparations as their own, and the 2021 study was sponsored by Handok, Inc., which employs one of its authors1,5,4,3.

Moderate Curcumin for arthritis pain, in general. A meta-analysis of 8 randomized trials of turmeric extract (about 1,000 mg a day of curcumin) found lower pain than placebo (mean difference −2.04, 95% CI −2.85 to −1.24, from 3 trials) and lower WOMAC scores (−15.36, 95% CI −26.9 to −3.77, from 4 trials), but no difference from pain medication in 5 trials; its authors say the trials are too few and too small for a definitive conclusion8. A later meta-analysis of 15 trials with 1,621 people with osteoarthritis found lower pain and WOMAC scores than placebo, effects similar to NSAIDs, and fewer adverse events than NSAIDs9. A network meta-analysis of 23 studies with 2,175 knee osteoarthritis patients put curcumin's pain reduction at −1.63 on a visual analog scale (95% CI −2.91 to −0.45) versus placebo10. These pool many preparations, so they aren't proof about Theracurmin.

Early Theracurmin for knee osteoarthritis. A double-blind trial of 50 patients (Kellgren-Lawrence grade II or III) found knee pain lower on Theracurmin with 180 mg of curcumin a day than on placebo at 8 weeks, except in those with the lowest pain scores at the start, with less need for celecoxib and no major side effects; the authors call its potential modest6. A 6-month open-label study of 50 people judged 34 (75.6%) "effective" and 11 not, with five dropouts and no placebo group17. A one-year trial in people who'd had knee cartilage surgery (43 examined) found no difference in symptom scores, but better cartilage stiffness and surface roughness on Theracurmin at second-look arthroscopy15. Theravalues financially supported the 2014 and 2022 trials, and two of the 2014 authors were its full-time employees6,15.

Early Memory. In an 18-month double-blind trial of 40 adults aged 51 to 84 without dementia, Theracurmin containing 90 mg of curcumin twice daily improved long-term retrieval memory (between-group effect size 0.68, p = 0.05) and attention on Trail Making A (0.67, p = 0.04) versus placebo, with brain PET scans in 15 people per group7. Forty people is small, and the p-values sit right at the edge.

Early Cancer. A phase I study gave Theracurmin with 200 mg (10 patients) or 400 mg (6 patients) of curcumin a day, alongside gemcitabine-based chemotherapy, to people with pancreatic or biliary tract cancer that standard chemotherapy had failed. It found no unexpected adverse events, and 3 patients continued for more than 9 months18. That's a safety study. It says nothing about whether curcumin helps treat the cancer.

Moderate Liver injury: the harm is real, though its rate is unknown. The US Drug-Induced Liver Injury Network found 10 turmeric-associated cases enrolled between 2004 and 2022, 6 of them since 2017: median age 56, 8 women, 5 hospitalized, and 1 death from acute liver failure, with injury typically appearing 1 to 4 months after starting. Seven of the 10 carried the gene variant HLA-B*35:01, an allele frequency of 0.450 against 0.056 to 0.069 in population controls, and 3 of the 7 products tested also contained piperine from black pepper11. In Italy, 28 spontaneous reports of acute hepatitis linked to turmeric supplements arrived in the first six months of 2019, and regulators acted19. In 7 cases from Tuscany, every product was a high-bioavailability formula at a high curcumin dose and most people improved after stopping; in 23 published cases, most patients were also taking another medication12. These are case series, so they don't give a rate, and none of these sources names Theracurmin11,19,12.

Rhonda Patrick on curcumin absorption

In FoundMyFitness Q&A #8, "Curcumin Bioavailability and Exercise—Plus Coffee and Brain Health," posted February 8, 2020, Rhonda Patrick compares curcumin formulations20. The show notes list piperine at about 20-fold more bioavailable than unformulated curcumin, micronized crystalline curcumin at 28-fold, and the Meriva phytosome at about 29-fold, and the episode takes up whether curcumin blunts the benefits of exercise20. In the transcript she points out that these figures come from separate studies against plain curcumin rather than head-to-head tests, and that studies like these are often funded by the formulation's maker. Theracurmin doesn't come up in the show notes or the transcript20. Her covering the topic doesn't mean she endorses me, this product, or this site.

About Integrative Therapeutics

Integrative Therapeutics, LLC, of Green Bay, Wisconsin, makes Theracurmin HP, and its label says Schwabe North America licenses the Theracurmin name from Theravalues Corporation13. Theravalues, of Tokyo, developed Theracurmin and financially supported the 2014 and 2022 knee trials1,6,15. The brand sits in the Schwabe group, not with Nestlé; the companies page has the ownership sources and the full profile.

Where I buy it

Prices aren't listed because they change.

Cautions

  • The label says not to take it if pregnant or nursing, and to consult a healthcare professional first for anyone with gallstones or a bile duct obstruction or on any medication13.
  • Liver injury has been reported with turmeric supplements, typically 1 to 4 months after starting in the US series, and the Tuscan cases all involved high-bioavailability products at high doses11,12. Better absorption is the point of this product, and it's also the feature those cases share. Tell the doctor you take it.
  • The joint and memory results come from small trials, and the stronger joint evidence is for curcumin in general, not Theracurmin6,7,8.
  • The maker's page claims support for detoxification pathways, cardiovascular function, and muscle recovery, and says the FDA hasn't evaluated those claims2.

References

  1. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, et al. Innovative preparation of curcumin for improved oral bioavailability. Biological & Pharmaceutical Bulletin. 2011;34(5):660-665.Lab or mechanistic studyPubMed 21532153 · DOI

    What it found: The original Theracurmin paper: after oral dosing, the colloidal-dispersion form's AUC was more than 40-fold higher than curcumin powder in rats and 27-fold higher in human volunteers given 30 mg, and it reduced blood acetaldehyde after drinking.

    Limits: The abstract gives no sample size, it measures blood levels rather than any health outcome, and an author is listed with Theravalues Corporation, which makes Theracurmin.

  2. Integrative Therapeutics. Theracurmin® HP | Integrative Therapeutics®. Integrative Therapeutics (integrativepro.com), 2026.Product pageRead

    What it found: The maker's product page: a serving is 2 capsules providing 600 mg of Theracurmin curcumin extract in both the 60- and 120-capsule sizes, with company claims that it is over 27 times more bioavailable than a standard curcumin extract (citing Sasaki 2011 and Sunagawa 2015) and supports detoxification pathways, cardiovascular function, and muscle recovery, plus the standard statement that the claims have not been evaluated by the FDA.

    Limits: Company marketing copy; the "27 times" figure comes from small absorption studies, the page is undated, and it shows no Amazon link, only a sign-in order page.

  3. Chung H, Yoon SH, Cho JY, Yeo HK, Shin D, Park JY. Comparative pharmacokinetics of Theracurmin, a highly bioavailable curcumin, in healthy adult subjects. International Journal of Clinical Pharmacology and Therapeutics. 2021;59(10):684-690.Randomized trialPubMed 34423771 · DOI

    What it found: Randomized three-period crossover study in 24 healthy adults comparing two Theracurmin products with unformulated curcumin powder: median time to peak was 1.5 to 3 hours versus 8 hours, and exposure ratios versus powder were 18.4 to 20.5 for peak concentration and 35.9 to 42.6 for AUC.

    Limits: Twenty-four healthy adults and blood levels only, and the study was sponsored by Handok, Inc., which employs one author (full text, Funding and Conflict of interest sections).

  4. Sunagawa Y, Hirano S, Katanasaka Y, Miyazaki Y, Funamoto M, Okamura N, et al. Colloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover study. Journal of Nutritional Science and Vitaminology. 2015;61(1):37-44.Randomized trialPubMed 25994138 · DOI

    What it found: Double-blind three-way crossover in 9 healthy adults comparing Theracurmin (six capsules, 182.4 mg curcumin) with BCM-95 (one capsule, 279.3 mg) and Meriva (two capsules, 152.5 mg): Theracurmin's peak was 10.7 times higher than BCM-95 and 5.6 times higher than Meriva, and its AUC 11.0 and 4.6 times higher.

    Limits: Nine people, products with different curcumin amounts so it is not dose-matched, blood levels rather than any health outcome, and the authors describe the Theracurmin capsules as their own.

  5. Morimoto T, Sunagawa Y, Katanasaka Y, Hirano S, Namiki M, Watanabe Y, et al. Drinkable preparation of Theracurmin exhibits high absorption efficiency--a single-dose, double-blind, 4-way crossover study. Biological & Pharmaceutical Bulletin. 2013;36(11):1708-1714.Randomized trialPubMed 24189415 · DOI

    What it found: Single-dose, double-blind, four-way crossover study in 24 healthy adults: the Theracurmin drink's 0 to 8 hour AUC was 1.5 to 4.0 times, and its peak plasma curcumin 1.8 to 3.8 times, that of three other curcumin beverages sold in Japan.

    Limits: Single doses in 24 healthy adults, measured as blood levels only, compared with other beverages rather than with a capsule, and the authors describe the Theracurmin preparations as their own.

  6. Nakagawa Y, Mukai S, Yamada S, Matsuoka M, Tarumi E, Hashimoto T, et al. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study. Journal of Orthopaedic Science. 2014;19(6):933-939.Randomized trialPubMed 25308211 · DOI

    What it found: Randomized double-blind trial in 50 patients with knee osteoarthritis (Kellgren-Lawrence grade II or III) given Theracurmin with 180 mg/day of curcumin or placebo for 8 weeks: knee pain on a visual analog scale was lower on Theracurmin at 8 weeks except in patients with the lowest starting scores, celecoxib dependence fell more, and there were no major side effects.

    Limits: Fifty people for 8 weeks, the abstract gives no numeric effect sizes, the authors call the potential modest, and the full text says Theravalues Corporation, which developed Theracurmin, financially supported the study and employed two authors full time.

  7. Small GW, Siddarth P, Li Z, Miller KJ, Ercoli L, Emerson ND, et al. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial. American Journal of Geriatric Psychiatry. 2018;26(3):266-277.Randomized trialPubMed 29246725 · DOI

    What it found: Eighteen-month, double-blind, placebo-controlled trial of 40 non-demented adults aged 51 to 84 given 90 mg Theracurmin twice daily (21 curcumin, 19 placebo). Curcumin improved long-term retrieval memory (between-group effect size 0.68, p = 0.05) and Trail Making A attention (0.67, p = 0.04), with PET changes in a subset of 30.

    Limits: Forty people, a specific bioavailable curcumin product, and the PET findings are associations.

  8. Daily JW, Yang M, Park S. Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Medicinal Food. 2016;19(8):717-729.Meta-analysisPubMed 27533649 · DOI

    What it found: Meta-analysis of 8 randomized trials of turmeric extract at about 1,000 mg/day of curcumin: pain on a visual analog scale was lower than with placebo (mean difference -2.04, 95% CI -2.85 to -1.24, 3 trials) and so was the WOMAC score (-15.36, 95% CI -26.9 to -3.77, 4 trials), while pain did not differ from pain medication (5 trials).

    Limits: Few, small trials of mixed preparations, the authors themselves say the number and quality of trials are not enough for definitive conclusions, and the first author lists an affiliation with Daily Manufacturing, Inc.

  9. Zeng L, Yu G, Hao W, Yang K, Chen H. The efficacy and safety of Curcuma longa extract and curcumin supplements on osteoarthritis: a systematic review and meta-analysis. Bioscience Reports. 2021;41(6):BSR20210817.Meta-analysisPubMed 34017975 · DOI

    What it found: Meta-analysis of 15 randomized trials with 1,621 participants with osteoarthritis: Curcuma longa extract and curcumin lowered pain and WOMAC scores versus placebo, had effects similar to NSAIDs with fewer adverse events, and the authors recommend using it for more than 12 weeks.

    Limits: The abstract gives no effect sizes, and it pools many different turmeric and curcumin preparations rather than a bioavailable form like Theracurmin.

  10. Zhao J, Liang G, Zhou G, Hong K, Yang W, Liu J, et al. Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis. Journal of Ethnopharmacology. 2024;321:117493.Meta-analysisPubMed 38036015 · DOI

    What it found: Bayesian network meta-analysis of 23 studies with 2,175 knee osteoarthritis patients: versus placebo, curcumin lowered pain on a visual analog scale (mean difference -1.63, 95% CI -2.91 to -0.45) and total WOMAC score (-18.85, 95% CI -29.53 to -8.76), and had fewer adverse reactions than NSAIDs (OR 0.51, 95% CI 0.25 to 0.94).

    Limits: Pools different curcumin products, doses, and study qualities, and the abstract does not report heterogeneity.

  11. Halegoua-DeMarzio D, Navarro V, Ahmad J, Avula B, Barnhart H, Barritt AS, et al. Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. The American Journal of Medicine. 2023;136(2):200-206.Cohort studyPubMed 36252717 · DOI

    What it found: Ten turmeric-related cases from the US Drug-Induced Liver Injury Network (2004 to 2022, 6 since 2017): median age 56, 8 women, hepatocellular injury in 9, 5 hospitalized, 1 died of acute liver failure; 7 carried HLA-B*35:01 (allele frequency 0.450 versus 0.056 to 0.069 in population controls), and turmeric was confirmed in all 7 products tested, 3 of which also contained piperine.

    Limits: A ten-case series, so it gives no rate of injury and does not say which brands were involved; latency was 1 to 4 months.

  12. Lombardi N, Crescioli G, Maggini V, Ippoliti I, Menniti-Ippolito F, Gallo E, et al. Acute liver injury following turmeric use in Tuscany: An analysis of the Italian Phytovigilance database and systematic review of case reports. British Journal of Clinical Pharmacology. 2021;87(3):741-753.Systematic reviewPubMed 32656820 · DOI

    What it found: Seven Tuscan reports of acute hepatitis to the Italian phytovigilance system (through September 2019) plus a systematic review of 23 published cases: in all 7 Tuscan cases the product was a high-bioavailability formulation with a high curcumin dose and most improved after stopping, and in the 23 published cases most patients were also taking another medication and 16 improved after stopping.

    Limits: Case reports and spontaneous reports cannot give how often it happens or prove cause, and many patients took other drugs.

  13. Integrative Therapeutics, LLC (label record in the NIH Dietary Supplement Label Database). Theracurmin HP (Integrative Therapeutics), label record 328352. NIH Office of Dietary Supplements, Dietary Supplement Label Database, January 23, 2025.Product pageRead

    What it found: Label record entered January 23, 2025 and not marked off market: 2 capsules per serving, 60 servings in a 120-capsule bottle, 600 mg of Theracurmin per serving, adults take 2 capsules daily or as a healthcare professional recommends, with warnings against use in pregnancy or nursing and a note to ask a professional about gallstones, bile duct obstruction, or medications; Theracurmin is a registered trademark of Theravalues Corporation used under license by Schwabe North America.

    Limits: A database copy of the label for the 120-capsule bottle, not the maker's current page, so I did not confirm the 60-capsule label or that nothing changed since January 2025.

  14. Integrative Therapeutics (label record in the NIH Dietary Supplement Label Database). Theracurmin HP (Integrative Therapeutics), earlier label record 76875. NIH Office of Dietary Supplements, Dietary Supplement Label Database, September 21, 2017.Product pageRead

    What it found: An earlier, off-market label (entered September 21, 2017; off market June 21, 2018): 60 capsules, 2 capsules per serving, Theracurmin 600 mg providing 30% curcumin (180 mg), with a typical first-week dose of 2 capsules or more once a day, then 1 capsule a day.

    Limits: An old label, shown only because it is the one I opened that gives the 30% curcumin (180 mg) figure; the current label lists 600 mg of Theracurmin without that breakdown.

  15. Nakagawa Y, Mori K, Yamada S, Mukai S, Hirose A, Nakamura R. The Oral Administration of Highly-Bioavailable Curcumin for One Year Has Clinical and Chondro-Protective Effects: A Randomized, Double-Blinded, Placebo-Controlled Prospective Study. Arthroscopy, Sports Medicine, and Rehabilitation. 2022;4(2):e393-e402.Randomized trialPubMed 35494290 · DOI

    What it found: Randomized double-blind trial in people who had knee cartilage surgery (50 enrolled, 43 examined) taking Theracurmin with 180 mg/day of curcumin or placebo for 12 months: pain and function scores did not differ between groups, but cartilage stiffness and surface roughness at second-look arthroscopy were better with Theracurmin.

    Limits: Small, surgical patients rather than the general public, symptoms did not differ between groups, one author lists an affiliation with Theravalues Corporation, and the full text says Theravalues financially supported the study.

  16. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemotherapy and Pharmacology. 2012;69(1):65-70.Lab or mechanistic studyPubMed 21603867 · DOI

    What it found: Six healthy volunteers took single 150 mg and then 210 mg doses of Theracurmin two weeks apart: peak plasma curcumin was 189 and 275 ng/ml, 24-hour exposure (AUC) was 2,649 and 3,649 ng/ml per hour, and half-life was 9.7 and 13.0 hours, with one case of grade 1 diarrhea.

    Limits: Six people, single doses, and blood levels only, so it shows absorption and short-term tolerability, not any benefit.

  17. Nakagawa Y, Mukai S, Yamada S, Murata S, Yabumoto H, Maeda T, et al. The Efficacy and Safety of Highly-Bioavailable Curcumin for Treating Knee Osteoarthritis: A 6-Month Open-Labeled Prospective Study. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2020;13:1179544120948471.Cohort studyPubMed 32848491 · DOI

    What it found: Open-label, uncontrolled six-month study of 50 people with knee osteoarthritis taking Theracurmin with 180 mg/day of curcumin: 34 (75.6%) were judged to be in the effective group and 11 in the not-effective group, five dropped out, and no major side effects were reported, including on blood chemistry.

    Limits: No placebo group or blinding, so improvement could be natural fluctuation or expectation, and the "effective" label is the authors' own.

  18. Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemotherapy and Pharmacology. 2013;71(6):1521-1530.Lab or mechanistic studyPubMed 23543271 · DOI

    What it found: Phase I study in patients with pancreatic or biliary tract cancer that had failed standard chemotherapy, given Theracurmin with 200 mg (10 patients) or 400 mg (6 patients) of curcumin daily alongside gemcitabine-based chemotherapy: median peak plasma curcumin was 324 and 440 ng/mL, there were no unexpected adverse events, and 3 patients continued for more than 9 months.

    Limits: A small phase I safety and blood-level study, so it says nothing about whether curcumin helps treat the cancer.

  19. Menniti-Ippolito F, Ippoliti I, Pastorelli AA, Altieri I, Scalise F, De Santis B, et al. Turmeric (Curcuma longa L.) food supplements and hepatotoxicity: an integrated evaluation approach. Annali dell'Istituto Superiore di Sanita. 2020;56(4):462-469.Cross-sectional studyPubMed 33346172 · DOI

    What it found: Italy's phytovigilance system received 28 spontaneous reports of acute hepatitis, mostly cholestatic, linked to turmeric supplements in the first six months of 2019; causality was at least possible in all but one, the products were tested for drugs, heavy metals, aflatoxins, pesticides, dyes, and pyrrolizidine alkaloids, and regulatory action followed.

    Limits: Spontaneous reports, so they show a signal rather than how common the injury is.

  20. Patrick R. Q&A #8: Curcumin Bioavailability and Exercise—Plus Coffee and Brain Health. FoundMyFitness, February 8, 2020.PodcastListen

    What it found: Rhonda Patrick's solo Q&A; the show notes compare curcumin formulations (piperine about 20-fold, micronized crystalline curcumin 28-fold, NovaSOL micellar curcumin, and Meriva phytosome about 29-fold more bioavailable than unformulated curcumin) and take up whether curcumin blunts exercise benefits, and in the transcript she says two human trials of PQQ used 20 mg a day and found better cognition and mitochondrial function.

    Limits: Members-only episode with a public summary and transcript; Theracurmin does not come up in either, the fold figures come from separate studies that she notes are not head-to-head comparisons, and the PQQ remark is her summary of two trials.